摘要
为比较雷替曲塞与卡培他滨用于晚期结直肠癌治疗的疗效与安全性,将我科2015年2月至2017年7月收治的90例晚期结直肠癌患者根据治疗方案不同分为观察组和对照组,观察组患者采用雷替曲塞治疗(48例),对照组患者采用卡培他滨治疗(42例),比较2组疗效和安全性。结果显示,观察组疾病控制率略高于对照组,但差异无统计学意义,P>0.05;观察组恶心呕吐及手足综合征发生率均明显低于对照组,P <0.05。结果表明,雷替曲塞用于晚期结直肠癌的治疗具有较好的疗效,且可减少不良反应。
To compare the effect and the safety of advanced colorectal carcinoma treated with Raltitrexed and with Capecitabine,90 patients with this disease who received treatment in author's dept.(2015-02-2017-07)were divided into observation group (48 cases,adopted Raltitrexed medication)and control one (42 cases,adopted Capecitabine medication),then both groups'effect and safety were compared.As results, even the disease control rate in observation group was slight higher than that of control group,but the difference had no statistical significance (P>0.05);in the incidence of nausea and vomiting,as well as hand-foot syndrome,observation group was significantly less than control group (P<0.05).Results show that Raltitrexed has better effect than Calgecitabine in the treatment of advanced colorectal carcinoma,and it can reduce incidence of untoward reaction.
作者
赵得堡
ZHAO De-bao(Medical Dept.of Oncology ,the Central Hospital of Nanyang City ,Nanyang ,Henan 473000)
出处
《中国肛肠病杂志》
2018年第11期12-13,共2页
Chinese Journal of Coloproctology
关键词
晚期结直肠癌
雷替曲塞
卡培他滨
疗效
安全性
Advanced colorectal carcinoma
Raltitrexed
Capecitabine
Effect
Safety
